125 related articles for article (PubMed ID: 20525919)
1. Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation.
Long-Boyle J; Huang J; Rydholm N; Smith A; Orchard P; Tolar J; Jacobson P
J Clin Pharmacol; 2011 May; 51(5):679-86. PubMed ID: 20525919
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
Petri CR; O'Donnell PH; Cao H; Artz AS; Stock W; Wickrema A; Hard M; van Besien K
Leuk Lymphoma; 2014 Dec; 55(12):2866-73. PubMed ID: 24564572
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
[TBL] [Abstract][Full Text] [Related]
4. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
5. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
Soni S; Abdel-Azim H; McManus M; Nemecek E; Sposto R; Woolfrey A; Frangoul H
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1134-1141. PubMed ID: 28396162
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Kebriaei P; Basset R; Ledesma C; Ciurea S; Parmar S; Shpall EJ; Hosing C; Khouri I; Qazilbash M; Popat U; Alousi A; Nieto Y; Jones RB; de Lima M; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1819-26. PubMed ID: 22750645
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Magenau J; Tobai H; Pawarode A; Braun T; Peres E; Reddy P; Kitko C; Choi S; Yanik G; Frame D; Harris A; Erba H; Kujawski L; Elenitoba-Johnson K; Sanks J; Jones D; Paczesny S; Ferrara J; Levine J; Mineishi S
Blood; 2011 Oct; 118(15):4258-64. PubMed ID: 21841163
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature.
Benitez LL; Gharibian K; Frame D; Mody R; Mora E
J Pediatr Hematol Oncol; 2017 Aug; 39(6):481-484. PubMed ID: 28538504
[TBL] [Abstract][Full Text] [Related]
10. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.
Patel YT; Jacus MO; Boulos N; Dapper JD; Davis AD; Vuppala PK; Freeman BB; Mohankumar KM; Throm SL; Gilbertson RJ; Stewart CF
Cancer Chemother Pharmacol; 2015 May; 75(5):897-906. PubMed ID: 25724157
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM
Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients.
Nijstad AL; Nierkens S; Lindemans CA; Boelens JJ; Bierings M; Versluys AB; van der Elst KCM; Huitema ADR
Br J Clin Pharmacol; 2021 Aug; 87(8):3218-3226. PubMed ID: 33444472
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation.
Wang H; Jones AK; Dvorak CC; Huang L; Orchard P; Ivaturi V; Long-Boyle J
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1603-1610. PubMed ID: 31002993
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Gandhi V; Plunkett W; Bonate PL; Du M; Nowak B; Lerner S; Keating MJ
Clin Cancer Res; 2006 Jul; 12(13):4011-7. PubMed ID: 16818700
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia.
Bonate PL; Craig A; Gaynon P; Gandhi V; Jeha S; Kadota R; Lam GN; Plunkett W; Razzouk B; Rytting M; Steinherz P; Weitman S
J Clin Pharmacol; 2004 Nov; 44(11):1309-22. PubMed ID: 15496649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
